Cervical cancer vaccine market set to increase at 12.1 percent CAGR
A recent report has predicted that the cervical cancer vaccine market will increase to $6bn by the end of the forecast period.
List view / Grid view
A recent report has predicted that the cervical cancer vaccine market will increase to $6bn by the end of the forecast period.
According to new research, innovation in drug delivery is accelerating in Europe, with Switzerland as Europe’s biggest drug delivery innovator.
Sir Andrew Dillion will be stepping down from his role as chief executive of NICE next year, after holding his position for 20 years.
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
XTANDI® sNDA seeks to add an indication for men with prostate cancer that's spread but is sensitive to hormone therapy.
Ningbo Huize Commodity Co has been sent a warning letter for cGMP violations, including data integrity issues.
A late-stage clinical trial for Imfinzi and an experimental treatment has not extended the lives of patients with advanced non-small cell lung cancer.
A study has found that between 2014 and 2016, the EMA and FDA had very little divergence in their marketing authorisation decisions.
The US HHS has committed to a contribution to help Merck manufacture its investigational V920 vaccine for the treatment of Ebola.
New research has found that of the 38 warning letters handed out by the FDA in 2019, the US and India received the vast majority.
A new biosimilar drug to treat osteoporosis is now available across Europe after the patent for its reference product expired.
Drug companies are still raising prices for brand-name prescription medicines but not as often or by as much as they used to.
Brüün has announced he will be leaving his role as CEO at the BPS and moving to a new role at the Royal College of Anaesthetists.
An investigational Zika vaccine currently being evaluated in a Phase I study has been given a Fast Track designation by the FDA.
A warning letter has been sent to Emcure Pharmaceuticals after an FDA facility inspection found that the company did not adequately investigate sterility failures.